Business Description
Acer Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US00444P1084
Description
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | -2.27 | |||||
| Debt-to-Equity | -0.97 | |||||
| Debt-to-EBITDA | -1.64 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 19.2 | |||||
| 3-Year EPS without NRI Growth Rate | 17.1 | |||||
| 3-Year FCF Growth Rate | 13.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.45 | |||||
| 9-Day RSI | 46.05 | |||||
| 14-Day RSI | 48.4 | |||||
| 6-1 Month Momentum % | -25.45 | |||||
| 12-1 Month Momentum % | -61.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.16 | |||||
| Quick Ratio | 0.05 | |||||
| Cash Ratio | 0.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.8 | |||||
| Shareholder Yield % | -62.98 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -240.73 | |||||
| ROIC % | -72.03 | |||||
| ROC (Joel Greenblatt) % | -14853.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 6.78 | |||||
| EV-to-EBIT | -2.57 | |||||
| EV-to-EBITDA | -2.58 | |||||
| EV-to-Forward-EBITDA | -1.18 | |||||
| EV-to-Forward-Revenue | 1.05 | |||||
| EV-to-FCF | -1.59 | |||||
| Earnings Yield (Greenblatt) % | -38.91 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACER
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acer Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.95 | ||
| Beta | -0.22 | ||
| Volatility % | 131.47 | ||
| 14-Day RSI | 48.4 | ||
| 14-Day ATR ($) | 0.087474 | ||
| 20-Day SMA ($) | 0.87876 | ||
| 12-1 Month Momentum % | -61.03 | ||
| 52-Week Range ($) | 0.5515 - 4.56 | ||
| Shares Outstanding (Mil) | 24.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acer Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acer Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Acer Therapeutics Inc Frequently Asked Questions
What is Acer Therapeutics Inc(ACER)'s stock price today?
The current price of ACER is $0.81. The 52 week high of ACER is $4.56 and 52 week low is $0.55.
When is next earnings date of Acer Therapeutics Inc(ACER)?
The next earnings date of Acer Therapeutics Inc(ACER) is 2023-11-18 Est..
Does Acer Therapeutics Inc(ACER) pay dividends? If so, how much?
Acer Therapeutics Inc(ACER) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers